Reimbursement Delays: Still Variable, Getting Even More So
The EU enlargement project may have just taken a big step forward, but when it comes to harmonization, there's still work to do. One of the most challenging aspects to doing business in Europe for pharma firms remains the complex and lengthy pricing and reimbursement negotiations required in each market in order to get drugs to patients. Despite EU guidelines limiting the reimbursement delay period to 180 days, half of the "old" EU member states still take far longer, according to data from Cambridge Pharma Consultancy (part of IMS Health).
You may also be interested in...
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.